Literature DB >> 24146041

CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Rachel J M Abbott1, Laura L Quinn, Alison M Leese, Harry M Scholes, Annette Pachnio, Alan B Rickinson.   

Abstract

EBV elicits primary CD8(+) T cell responses that, by T cell cloning from infectious mononucleosis (IM) patients, appear skewed toward immediate early (IE) and some early (E) lytic cycle proteins, with late (L) proteins rarely targeted. However, L Ag-specific responses have been detected regularly in polyclonal T cell cultures from long-term virus carriers. To resolve this apparent difference between responses to primary and persistent infection, 13 long-term carriers were screened in ex vivo IFN-γ ELISPOT assays using peptides spanning the two IE, six representative E, and seven representative L proteins. This revealed memory CD8 responses to 44 new lytic cycle epitopes that straddle all three protein classes but, in terms of both frequency and size, maintain the IE > E > L hierarchy of immunodominance. Having identified the HLA restriction of 10 (including 7 L) new epitopes using memory CD8(+) T cell clones, we looked in HLA-matched IM patients and found such reactivities but typically at low levels, explaining why they had gone undetected in the original IM clonal screens. Wherever tested, all CD8(+) T cell clones against these novel lytic cycle epitopes recognized lytically infected cells naturally expressing their target Ag. Surprisingly, however, clones against the most frequently recognized L Ag, the BNRF1 tegument protein, also recognized latently infected, growth-transformed cells. We infer that BNRF1 is also a latent Ag that could be targeted in T cell therapy of EBV-driven B-lymphoproliferative disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24146041      PMCID: PMC5580796          DOI: 10.4049/jimmunol.1301629

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

Authors:  A L Chapman; A B Rickinson; W A Thomas; R F Jarrett; J Crocker; S P Lee
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

3.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing.

Authors:  X Saulquin; M Bodinier; M A Peyrat; A Hislop; E Scotet; F Lang; M Bonneville; E Houssaint
Journal:  Eur J Immunol       Date:  2001-03       Impact factor: 5.532

5.  Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.

Authors:  Rika Draenert; Marcus Altfeld; Christian Brander; Nesli Basgoz; Colleen Corcoran; Alysse G Wurcel; David R Stone; Spyros A Kalams; Alicja Trocha; Marylyn M Addo; Philip J R Goulder; Bruce D Walker
Journal:  J Immunol Methods       Date:  2003-04-01       Impact factor: 2.303

6.  The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.

Authors:  Simon Jochum; Andreas Moosmann; Stephan Lang; Wolfgang Hammerschmidt; Reinhard Zeidler
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

7.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.

Authors:  Victoria A Pudney; Alison M Leese; Alan B Rickinson; Andrew D Hislop
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

Review 8.  Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity.

Authors:  Martin Rowe; Jianmin Zuo
Journal:  Microbes Infect       Date:  2010-02-01       Impact factor: 2.700

Review 9.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

10.  The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.

Authors:  Jianmin Zuo; Andrew Currin; Bryan D Griffin; Claire Shannon-Lowe; Wendy A Thomas; Maaike E Ressing; Emmanuel J H J Wiertz; Martin Rowe
Journal:  PLoS Pathog       Date:  2009-01-02       Impact factor: 6.823

View more
  21 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  T cell epitope screening of Epstein-Barr virus fusion protein gB.

Authors:  Haiwen Chen; Xiao Zhang; Shanshan Zhang; Xiaobing Duan; Tong Xiang; Xiang Zhou; Wanlin Zhang; Xinyu Zhang; Qisheng Feng; Yinfeng Kang; Jiangping Li; Lan Deng; Liang Wang; Xing Lv; Musheng Zeng; Yi-Xin Zeng; Miao Xu
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

3.  T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.

Authors:  Melissa J Rist; Michelle A Neller; Jacqueline M Burrows; Scott R Burrows
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

4.  The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+ T Cells.

Authors:  Josef Mautner; Uta Behrends; Dinesh Adhikary; Julia Damaschke
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

Review 5.  Infectious mononucleosis.

Authors:  Henry H Balfour; Samantha K Dunmire; Kristin A Hogquist
Journal:  Clin Transl Immunology       Date:  2015-02-27

6.  Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.

Authors:  Laura L Quinn; Jianmin Zuo; Rachel J M Abbott; Claire Shannon-Lowe; Rosemary J Tierney; Andrew D Hislop; Martin Rowe
Journal:  PLoS Pathog       Date:  2014-08-21       Impact factor: 6.823

Review 7.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

Review 8.  Dendritic cells during Epstein Barr virus infection.

Authors:  Christian Münz
Journal:  Front Microbiol       Date:  2014-06-20       Impact factor: 5.640

9.  Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice.

Authors:  Olga Antsiferova; Anne Müller; Patrick C Rämer; Obinna Chijioke; Bithi Chatterjee; Ana Raykova; Raquel Planas; Mireia Sospedra; Anatoliy Shumilov; Ming-Han Tsai; Henri-Jacques Delecluse; Christian Münz
Journal:  PLoS Pathog       Date:  2014-08-28       Impact factor: 6.823

10.  Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.

Authors:  Jill M Brooks; Heather M Long; Rose J Tierney; Claire Shannon-Lowe; Alison M Leese; Martin Fitzpatrick; Graham S Taylor; Alan B Rickinson
Journal:  PLoS Pathog       Date:  2016-04-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.